About The Study: This cross-sectional study suggests that despite increasing clearance of artificial intelligence (AI)/machine learning (ML) devices, standardized efficacy, safety, and risk assessment by the Food and Drug Administration (FDA) are lacking. Dedicated regulatory pathways and post-market surveillance of AI/ML safety events may address these challenges.
Corresponding Author: To contact the corresponding author, Ravi B. Parikh, MD, MPP, email ravi.bharat.parikh@emory.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamahealthforum.2025.3351)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2025.3351?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=092625
About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.
Journal
JAMA Health Forum